WO2008069972A3 - Systèmes destinés à mettre fin à l'usage du tabac - Google Patents

Systèmes destinés à mettre fin à l'usage du tabac Download PDF

Info

Publication number
WO2008069972A3
WO2008069972A3 PCT/US2007/024641 US2007024641W WO2008069972A3 WO 2008069972 A3 WO2008069972 A3 WO 2008069972A3 US 2007024641 W US2007024641 W US 2007024641W WO 2008069972 A3 WO2008069972 A3 WO 2008069972A3
Authority
WO
WIPO (PCT)
Prior art keywords
systems
tobacco use
effecting cessation
cessation
effecting
Prior art date
Application number
PCT/US2007/024641
Other languages
English (en)
Other versions
WO2008069972A2 (fr
Inventor
Igor Gonda
Original Assignee
Aradigm Corp
Igor Gonda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/932,402 external-priority patent/US20080138294A1/en
Priority claimed from US11/931,867 external-priority patent/US20080138398A1/en
Priority claimed from US11/931,921 external-priority patent/US20080138399A1/en
Priority claimed from US11/932,437 external-priority patent/US8256433B2/en
Application filed by Aradigm Corp, Igor Gonda filed Critical Aradigm Corp
Priority to EP07867592A priority Critical patent/EP2086527A4/fr
Publication of WO2008069972A2 publication Critical patent/WO2008069972A2/fr
Publication of WO2008069972A3 publication Critical patent/WO2008069972A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne d'une manière générale un système, une trousse et un procédé qui permettent de traiter des états physiques réagissant à la nicotine thérapeutique. Plus spécifiquement, l'invention concerne l'administration pulmonaire d'une formulation contenant de la nicotine afin de mettre fin au tabagisme.
PCT/US2007/024641 2006-12-01 2007-11-30 Systèmes destinés à mettre fin à l'usage du tabac WO2008069972A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07867592A EP2086527A4 (fr) 2006-12-01 2007-11-30 Systèmes destinés à mettre fin à l'usage du tabac

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US86823806P 2006-12-01 2006-12-01
US60/868,238 2006-12-01
US91104407P 2007-04-10 2007-04-10
US60/911,044 2007-04-10
US91318507P 2007-04-20 2007-04-20
US60/913,185 2007-04-20
US91651007P 2007-05-07 2007-05-07
US60/916,510 2007-05-07
US91719007P 2007-05-10 2007-05-10
US60/917,190 2007-05-10
US98207007P 2007-10-23 2007-10-23
US60/982,070 2007-10-23
US11/932,402 US20080138294A1 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
US11/931,867 US20080138398A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/931,867 2007-10-31
US11/932,437 2007-10-31
US11/931,921 US20080138399A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/931,921 2007-10-31
US11/932,437 US8256433B2 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
US11/932,402 2007-10-31

Publications (2)

Publication Number Publication Date
WO2008069972A2 WO2008069972A2 (fr) 2008-06-12
WO2008069972A3 true WO2008069972A3 (fr) 2008-10-30

Family

ID=39492806

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/024636 WO2008069970A2 (fr) 2006-12-01 2007-11-30 Formulations de nicotine, trousses, systèmes et procédés d'utilisation
PCT/US2007/024641 WO2008069972A2 (fr) 2006-12-01 2007-11-30 Systèmes destinés à mettre fin à l'usage du tabac

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024636 WO2008069970A2 (fr) 2006-12-01 2007-11-30 Formulations de nicotine, trousses, systèmes et procédés d'utilisation

Country Status (2)

Country Link
EP (2) EP2086317A4 (fr)
WO (2) WO2008069970A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2010213244A1 (en) * 2009-02-11 2010-08-19 Heglund, A.S. A composition for buccal absorption of nicotine for the purpose of smoking cessation
WO2011023796A1 (fr) * 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox destiné au traitement de l'addiction
TWI484958B (zh) * 2011-05-19 2015-05-21 Heglund A S 用於戒菸之口腔吸收尼古丁組成物
EP2729148A4 (fr) 2011-07-06 2015-04-22 Parkinson S Inst Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
RU2541312C2 (ru) * 2011-08-31 2015-02-10 Александр Васильевич Иващенко Фармацевтическая композиция, способ ее получения и устройство для ее применения
US10556011B2 (en) 2011-12-02 2020-02-11 Joshua D. Levine Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
WO2015042412A1 (fr) 2013-09-20 2015-03-26 E-Nicotine Technology. Inc. Dispositifs et procédés de modification de dispositifs de distribution
CA2974324A1 (fr) 2015-01-28 2016-08-04 Zita S. Netzel Procedes et systemes d'administration de medicament
CA2977814A1 (fr) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Systeme d'entree d'etat de manque et de support
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US20170071248A1 (en) 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CA3049529A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
MX2019010263A (es) * 2017-03-07 2019-10-09 Philip Morris Products Sa Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099999A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of treating depression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097443T3 (es) * 1992-02-20 1997-04-01 Wielligh Johannes Louw Kot Von Producto para ayudar a los fumadores a abandonar el habito.
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
EP1218048A4 (fr) * 1999-07-16 2009-08-26 Aradigm Corp Systeme permettant d'arreter de fumer
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099999A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of treating depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2086527A4 *

Also Published As

Publication number Publication date
EP2086317A2 (fr) 2009-08-12
WO2008069970A3 (fr) 2008-10-16
WO2008069972A2 (fr) 2008-06-12
EP2086317A4 (fr) 2010-03-03
EP2086527A4 (fr) 2010-03-03
WO2008069970A2 (fr) 2008-06-12
EP2086527A2 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
WO2008069972A3 (fr) Systèmes destinés à mettre fin à l'usage du tabac
WO2007087431A3 (fr) Pulvérisation sublinguale de fentanyle
HK1133994A1 (en) Low fire spreading cigarette, wrapping paper for the cigarette, and method of producing wrapping paper
UA88172C2 (ru) Способ изготовления фильтра курительного изделия с ароматизатором (варианты), курительное изделие (варианты) и фильтр курительного изделия (варианты)
WO2009017837A3 (fr) Aérosol sublingual de fentanyl
WO2012005885A3 (fr) Produit nutraceutique contenant de l'anatabine et du maté
HK1146485A1 (fr)
WO2009141321A3 (fr) Gommes à mâcher pouvant être conditionnées en comprimés
WO2007091267A3 (fr) Administration pulmonaire d'un inhibiteur de la protéinase alpha-1
MX2010003550A (es) Forma de dosificacion intraoral con multiples porciones con propiedades organolepticas.
HK1154761A1 (en) Method for the treatment of tobacco, tobacco and smoking article
WO2009108383A3 (fr) Dérivés de xanthine substitués
WO2011117733A8 (fr) Article à fumer avec système de distribution d'arôme
WO2009115160A3 (fr) Composition à mâcher et utilisation
WO2008144720A3 (fr) Compositions et procédés pour le traitement de troubles respiratoires
WO2007073911A3 (fr) Masquage de gout pour poudres
AP2150A (en) Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication.
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
WO2009010810A3 (fr) Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a
WO2008155390A3 (fr) Utilisation d'inhibiteurs de sirtuines et/ou de l'ampk dans la préparation d'un médicament destiné au traitement des maladies à polyalanine
WO2007081808A3 (fr) Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
WO2008012086A3 (fr) Dérivés de méthotrexate de liaison protéique et médicaments contenant lesdits dérivés
WO2008122728A3 (fr) Procédé de traitement nématocide des plantes à base d'eugénol et de lécithine(s) et/ou dérivés
WO2007100430A3 (fr) Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
WO2006060759A3 (fr) Composition contenant un liposome a stabilisation sterique et une triamcinolone pour le traitement du tractus respiratoire d'un mammifere

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780050167.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867592

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007867592

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE